9 result(s) displayed (1 - 9 of 9):

Danone ends JV saga (from Corporate Dealmaker)

A disgruntled Groupe Danone SA dumped its longtime joint venture partner Hangzhou Wahaha Group by selling its 51% stake in the JV. The Deal Pipeline (subscription required) cites a deal value of several hundred million dollars paid by the Chinese soft drinks maker. The two failed to resolve trademark disputes...

Posted on September 30, 2009 5:05 PM

Bristol-Myers proposes $4.5B ImClone acquisition (from Corporate Dealmaker)

Bristol-Myers Squibb Co. has initiated another step on its path from a diversified health and consumer products company to a focused biopharmaceutical firm. On Thursday morning Bristol-Myers chairman and CEO James Cornelius sent a letter to ImClone Systems Inc.'s chairman Carl Icahn about acquiring the company for $60 per...

Posted on July 31, 2008 8:56 AM

GE plays the spinoff card (from Corporate Dealmaker)

When General Electric Co. CEO Jeff Immelt put the company's appliance unit on the block two months ago, he also held out the possibility of a spinoff to shareholders. Thursday he said GE plans to spin off the entire commercial and industrial group to shareholders -- though he remains open...

Posted on July 10, 2008 4:02 PM

Bristol-Myers continues to morph with Kosan buy (from Corporate Dealmaker)

Drug developer Bristol-Myers Squibb Co. made another deal as it tries to focus on its pharmaceutical business, paying a 233% premium for cancer therapeutics company Kosan Biosciences. Bristol is paying $190 million cash hoping Kosan's late-stage drug Hsp90, among others, will come to market and bring in a few hundred...

Posted on May 30, 2008 7:56 AM

More on the divestiture wave (from Corporate Dealmaker)

Building on our previous post on divestitures, we spoke with Andy Wilson, Deloitte's & Touche's national managing partner for divestitures services, and Jefferey Weirens, national managing director of Deloitte's carve-out and merger integration practice. By Deloitte's reckoning, in 2007 the number of corporate sales of units worth $1 billion or...

Posted on May 8, 2008 2:02 PM

IPO plans for Mead Johnson, but Bristol's options are open (from Corporate Dealmaker)

Since Bristol-Myers Squibb Co. announced a strategic review for its Mead Johnson division, maker of infant formula Enfamil and other products, there's been speculation -- some of it here -- about who might buy the unit. Thursday, along with its quarterly results, the restructuring company announced the following:Bristol-Myers Squibb currently...

Posted on April 24, 2008 11:10 AM

Nestlé deals, organic growth boost sales to $26B (from Corporate Dealmaker)

In the first quarter, Nestlé SA reached sales of Sfr25.7 billion ($25.6 billion), up 6.0% over the same period last year. The company reported sales benefited from strong organic growth of 9.8%, including 4.5% real internal growth (the increase in quantities sold at last year's prices, excluding exchange rate effects...

Posted on April 22, 2008 1:26 PM

After Alcon deal, Nestle well positioned to bid for Mead Johnson (from Corporate Dealmaker)

News of Novartis AG buying Alcon Inc. from Nestle SA brings several thoughts to mind. The first, noted in Andrew Bulkeley's article in The Deal, is that the $11 billion in cash Nestle will reap in the first step of the deal is more than enough to pay for the...

Posted on April 7, 2008 1:42 PM

Bristol-Myers taps dealmaker as new CFO (from Corporate Dealmaker)

On March 31, Andrew Bonfield, executive vice president and chief financial officer of Bristol-Myers Squibb Co., will relinquish his role to Jean-Marc Huet. Huet (pictured) comes to BMS from the world of baby food. He was the engineer behind Amsterdam-based Royal Numico NV's acquisition strategy and their eventual $16.8 billion...

Posted on March 5, 2008 12:08 PM